Daniel Brennan, an analyst from TD Cowen, maintained the Hold rating on Becton Dickinson. The associated price target is $183.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Daniel Brennan’s rating is based on Becton Dickinson’s strategic decision to separate its Biosciences & Diagnostics Solutions through a combination with Waters Corporation. This move is expected to transform BDX into a more focused and innovative medical technology company, enhancing its growth potential and capital flexibility. The transaction is structured as a tax-efficient Reverse Morris Trust, which is anticipated to unlock approximately $8 billion in value for shareholders.
The decision to hold the stock reflects the potential benefits of the deal, including the cultural compatibility and strong financial profile of Waters as a partner. BDX shareholders will own a significant portion of the new entity, allowing them to benefit from future growth. However, the rating suggests a cautious approach, as the full impact of the transaction will unfold over time, with the deal expected to close by the end of the first quarter of 2026.
Brennan covers the Healthcare sector, focusing on stocks such as Exact Sciences, Thermo Fisher, and GeneDx Holdings. According to TipRanks, Brennan has an average return of 10.7% and a 47.20% success rate on recommended stocks.